Reuters logo
Merck and Endocyte's ovarian cancer drug fails in trial
May 2, 2014 / 12:40 PM / in 3 years

Merck and Endocyte's ovarian cancer drug fails in trial

(Reuters) - Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.

The trial was testing the drug, vintafolide, in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), compared to PLD plus a placebo.

An independent safety committee reviewing the trial had recommended that it be halted, the companies said in separate statements.

Reporting by Esha Dey in Bangalore; Editing by Maju Samuel

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below